Estradiol Valerate Combined with Dienogest: a New Concept Contraceptive Pill for Women With a Heavy Menstrual Bleeding

Sundström Poromaa I

J. Reproduktionsmed. Endokrinol 2011; 8 (Sonderheft 1), 219-221
Thomas Staudinger
Maurice Kienel

ECMO
für die Kitteltasche

2. Auflage: Jänner 2019
ISBN 978-3-901299-65-0
78 Seiten, div. Abbildungen
19.80 EUR

Bestellen Sie noch heute Ihr Exemplar auf
www.kup.at/cd-buch/75-bestellung.html
I. Sundström Poromaa

**Introduction**

In order to improve tolerability and safety, the development of a combined oral contraceptive containing estradiol has been the Holy Grail of pharmaceutical research and development for decades. Finally, in 2009 the first contraceptive pill containing estradiol in combination with dienogest (E₂V/DNG; Qlaira®) became available across Europe and spread globally. Although the safety of an estradiol-containing oral contraceptive in terms of venous thromboembolism remains to be proven by future studies, this new concept pill is an important addition to our contraceptive repertoire.

“The development of a combined oral contraceptive containing estradiol has been the Holy Grail of pharmaceutical research and development for decades.”

Historically, the main problem with estradiol-containing oral contraceptives (combined with progestogens such as norethisterone acetate, desogestrel or cyproterone acetate) was the lack of sufficient cycle control. Although reliable contraceptive efficacy was achieved in clinical trials, the high incidence of bleeding irregularities rendered these preparations unsuitable for general use. In clinical trials of estradiol-containing contraceptive pills, the number of women who reported spotting varied between 20% and 54%, and breakthrough bleeding occurred in 25–39% of women. The discontinuation rates for bleeding irregularities varied between 10% and 42% [1–7], or were cited as the main reason for discontinuation [8].

Clearly, an important step towards acceptable cycle control in estradiol-containing pills has been the development of new progestogens. Dienogest was chosen because of prior extensive experience with it and because of its pronounced effect on the endometrium [9, 10]. Another important step for improving cycle control is the dynamic four-phasic dosing regimen. Hence, the E₂V/DNG treatment cycle consists of an estradiol step-down and a progestogen step-up over 26 days to ensure estrogen dominance in the early part of the cycle and progestogen dominance in the mid-to late part of the cycle. Together with 2 placebo days, this results in a treatment cycle of 28 days.

From the user’s point of view, apart from the differences in design of the treatment cycle, E₂V/DNG offers reliable contraceptive efficacy and cycle control comparable to that of ethinylestradiol- (EE-) containing pills [11–14]. However, the new preparation promises additional benefits to those available with existing combined oral contraceptives, especially for women with heavy menstrual bleeding.

**Contraceptive Efficacy**

Data on the contraceptive efficacy of the new E₂V/DNG combination have been derived from three large-scale clinical trials conducted in Europe and North America [12–14]. A total of 2266 women were included in the trials. The Pearl index and adverse events included in the European summary of product characteristics are based on pooled analyses of these three pivotal studies. Accordingly, the Pearl index for method failure in women aged 18–35 years was 0.51 imately 10.0% [12]. The most frequent adverse events (upper limit of 95% CI: 0.97) and the Pearl index for potentially related to the study drug included breast method plus user failure was 1.01 (upper limit of 95% CI: 1.59, including incorrect or non-use of the women were either satisfied or very satisfied with the method). Adverse reactions were reported by approx-new pill [12, 13].

**Added Benefits of E₂V/DNG**

The potential use of E₂V/DNG in women with heavy menstrual bleeding was suggested by the positive results of a cycle control study. In a randomized double-blind study E₂V/DNG was compared with low-dose EE (20 µg) and levonorgestrel (EE/LNG), with bleeding pattern and cycle control as the main outcome measures [12]. Overall, 798 women between 18 and 50 years of age were randomized to seven cycles of E₂V/DNG or EE/LNG (399 in each treatment group). The primary efficacy endpoints included the number of bleeding/spotting days, the number and length of bleeding/spotting episodes, and the incidence and characteristics of withdrawal and inracyclic bleeding during two 90-day reference periods.

“The potential use of E2V/DNG in women with heavy menstrual bleeding was suggested by the positive results of a cycle control study.”

Overall, the number of bleeding/spotting days during both 90-day reference intervals was significantly lower among E₂V/DNG users (17.3 ± 10.4 vs 21.5 ± 8.6 in EE/LNG users, first reference period). Similarly, significantly fewer bleeding/spotting episodes were reported by E₂V/DNG users than by EE/ LNG users (3.7 ± 1.4 vs 4.1 ± 0.9, first reference period)
More women on E2V/DNG reported absence of scheduled withdrawal bleeding. The mean proportion of women who experienced no scheduled withdrawal bleeding (mean over 1–7 cycles) was 19.4% in the E2V/DNG group and 7.7% in the EE/LNG group. In all 7 cycles of treatment, scheduled withdrawal bleeding was absent in significantly more women in the E2V/DNG group (p < 0.0001). Adapted from [12].

Both studies indicated that women treated with E2V/DNG had a significantly greater reduction in mean menstrual blood loss compared with placebo users. E2V/DNG users in the North American study had a mean blood loss reduction of –353 ml during the 90-day efficacy period, whereas the corresponding reduction for placebo users was –130 ml [15]. Similarly, the European study reported a significant difference in the adjusted mean difference of menstrual blood loss of –373 ml [16]. The marked decline in mean blood loss was already apparent from cycle 2 and was accompanied by significant improvements in haemoglobin and ferritin concentrations [15, 16].

"The marked decline in mean blood loss was already apparent from cycle 2 and was accompanied by significant improvements in haemoglobin and ferritin concentrations."

According to the study protocols of both trials, women with complaints of heavy and/or prolonged menstrual bleeding underwent a 90-day run-in period to confirm the presence of heavy menstrual bleeding (at least two episodes each with a blood loss volume of at least 80 ml), prolonged bleeding (at least two episodes lasting at least 8 days) and/or frequent bleeding (more than five bleeding episodes with at least 20 bleeding days overall). The bleeding data were rigorously collected by electronic daily bleeding diaries and collection of sanitary items. The total menstrual blood loss volume from the sanitary products was calculated by the alkaline haematin method. Eligible women were subsequently randomized in a 2:1 ratio to either E2V/DNG or placebo for six treatment cycles. The European study randomized 231 women and the North American study 190 women.

Although the safety of an estradiol-containing oral contraceptive in terms of venous thromboembolism remains to be proven by future studies, the concept of an estradiol-containing contraceptive pill is an important addition to our contraceptive repertoire. This first of a new class oral contraceptive may be especially useful in women with heavy menstrual bleeding.
References:


5. Csemiczky G, Dieben T, Coeling Bennink HJ, Landgren BM. The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days. Contraception 1996; 54: 303–8.


Haftungsausschluss

Bitte beachten Sie auch diese Seiten:
Impressum  Disclaimers & Copyright  Datenschutzerklärung